BIOMAT Database Logo BIOMAT Database Logo

Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. 2007

Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
University of Alabama at Birmingham, Division of Clinical Pharmacology, Birmingham, AL, USA.

BACKGROUND Intracellular nucleoside reverse transcriptase inhibitor triphosphate (NRTI-TP) concentrations are crucial in suppressing HIV replication. Little is known about how commonly used dual-NRTI regimens affect the intracellular levels of NRTI-TPs, the active form of these drugs. This study investigates the effect of dual-NRTI therapy in intracellular NRTI-TP levels. METHODS NRTI and NRTI-TP concentrations were evaluated in HIV-infected patients receiving either lamivudine (3TC) and stavudine (d4T) or lamivudine with zidovudine (ZDV); NRTI and NRTI-TP concentrations were determined using a validated HPLC/MS/MS method. Plasma HIV-1 RNA levels were determined at baseline and monthly to examine the relationship between NRTI-TP concentrations and plasma HIV-1 RNA. RESULTS Forty-one subjects completed the study. 3TC-TP significantly increased between day 1 and week 28 from 1.48 to 5.00 pmol/10(6) peripheral blood mononuclear cells (PBMC; P < 0.0001). NRTI-TP concentrations for d4T and ZDV did not significantly increase, with values at week 28 of 0.011 and 0.02 pmol/10(6) PBMC, respectively. Mean NRTI-TP/plasma ratios were 3%, 0.007% and 0.05% for 3TC, d4T and ZDV, respectively. Linear relationships were observed between ZDV- and 3TC-TP and changes in plasma HIV-1 RNA. CONCLUSIONS Of the three drugs studied, only 3TC-TP levels increased significantly between day 1 and week 28. ZDV-TP and 3TC-TP levels were unaffected by dual-NRTI therapy relative to monotherapy, regardless of the combination (3TC-ZDV or 3TC-d4T). Intracellular levels of d4T-TP were similar to previous reports for dual-NRTI therapy; however, in the case of d4T, these values appear lower than those achieved with d4T monotherapy.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008297 Male Males
D003570 Cytidine Triphosphate Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety. CTP,CRPPP,Magnesium CTP,Mg CTP,Triphosphate, Cytidine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013942 Thymine Nucleotides Phosphate esters of THYMIDINE in N-glycosidic linkage with ribose or deoxyribose, as occurs in nucleic acids. (From Dorland, 28th ed, p1154) Thymidine Phosphates,Nucleotides, Thymine,Phosphates, Thymidine
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054306 Dideoxynucleotides The phosphate esters of DIDEOXYNUCLEOSIDES. Dideoxynucleotide Triphosphates,ddNTPs,Triphosphates, Dideoxynucleotide

Related Publications

Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.
December 2008, The Journal of infectious diseases,
Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
April 2008, The Journal of antimicrobial chemotherapy,
Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
March 2001, AIDS (London, England),
Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
[Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients].
February 2007, Enfermedades infecciosas y microbiologia clinica,
Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
Long-term efficacy of dual nucleoside reverse transcriptase inhibitor antiretroviral therapy in HIV-1 infection.
July 2002, AIDS (London, England),
Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
January 2007, Antiviral therapy,
Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
Nucleoside reverse-transcriptase inhibitor use, cirrhosis, and end-stage liver disease in HIV-infected patients.
November 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.
August 2006, The Journal of antimicrobial chemotherapy,
Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.
November 2006, British journal of clinical pharmacology,
Jeff D Moore, and Edward P Acosta, and Victoria A Johnson, and Roland Bassett, and Joseph J Eron, and Margaret A Fischl, and Mary C Long, and Daniel R Kuritzkes, and Jean-Pierre Sommadossi
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
October 2010, Therapeutic drug monitoring,
Copied contents to your clipboard!